Alden Yuanhong Lai1, Katherine C Smith2, Jon S Vernick3, Corey S Davis4, G Caleb Alexander5, Lainie Rutkow6. 1. a Department of Health Policy & Management , Johns Hopkins Bloomberg School of Public Health , Baltimore , Maryland , USA. 2. b Department of Health, Behavior & Society , Johns Hopkins Bloomberg School of Public Health , Baltimore , Maryland , USA. 3. c Department of Health Policy & Management , Johns Hopkins Bloomberg School of Public Health , Baltimore , Maryland , USA. 4. d Network for Public Health Law , Los Angeles , California , USA. 5. e Department of Epidemiology , Johns Hopkins Bloomberg School of Public Health , Baltimore , MD , USA. 6. f Department of Health Policy & Management , Johns Hopkins Bloomberg School of Public Health , Baltimore , MD , USA.
Abstract
BACKGROUND: Opioid-related injuries and deaths continue to present challenges for public health practitioners. Prescription Drug Monitoring Programs (PDMPs) are a prevalent policy option intended to address problematic opioid pain reliever (OPR) prescribing, but previous research has not thoroughly characterized their unintended consequences. OBJECTIVES: To examine state actors' perceptions of the unintended consequences of PDMPs. METHODS: We conducted 37 interviews with PDMP staff, law enforcement officials, and administrative agency employees in Florida, Kentucky, New Jersey, and Ohio from May 2015 to June 2016. RESULTS: We identified six themes from the interviews. Perceived negative unintended consequences included: access barriers for those with medical needs, heroin use as OPR substitute and related deaths, and need for adequate PDMP security infrastructure and management. Perceived positive unintended consequences were: community formation and problem awareness, proactive population-level OPR monitoring, and increased knowledge about population-level drug diversion. Conclusions/Importance: State actors perceive a range of both negative and positive unintended consequences of PDMPs. Our findings suggest that there may be unintended risks of PDMPs that states should address, but also opportunities to maximize certain benefits.
BACKGROUND: Opioid-related injuries and deaths continue to present challenges for public health practitioners. Prescription Drug Monitoring Programs (PDMPs) are a prevalent policy option intended to address problematic opioid pain reliever (OPR) prescribing, but previous research has not thoroughly characterized their unintended consequences. OBJECTIVES: To examine state actors' perceptions of the unintended consequences of PDMPs. METHODS: We conducted 37 interviews with PDMP staff, law enforcement officials, and administrative agency employees in Florida, Kentucky, New Jersey, and Ohio from May 2015 to June 2016. RESULTS: We identified six themes from the interviews. Perceived negative unintended consequences included: access barriers for those with medical needs, heroin use as OPR substitute and related deaths, and need for adequate PDMP security infrastructure and management. Perceived positive unintended consequences were: community formation and problem awareness, proactive population-level OPR monitoring, and increased knowledge about population-level drug diversion. Conclusions/Importance: State actors perceive a range of both negative and positive unintended consequences of PDMPs. Our findings suggest that there may be unintended risks of PDMPs that states should address, but also opportunities to maximize certain benefits.
Entities:
Keywords:
Prescription opioids; prescription drug monitoring programs; public health practice; qualitative; unintended consequences
Authors: Magdalena Cerdá; William R Ponicki; Nathan Smith; Ariadne Rivera-Aguirre; Corey S Davis; Brandon D L Marshall; David S Fink; Stephen G Henry; Alvaro Castillo-Carniglia; Garen J Wintemute; Andrew Gaidus; Paul J Gruenewald; Silvia S Martins Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Mina Hong; Sarah Seymour; Thomas J Stopka; Lane Bandanza; Erin Crocker; Allison Morgan; Leo Beletsky Journal: J Addict Med Date: 2022 May-Jun 01 Impact factor: 4.647
Authors: Silvia S Martins; William Ponicki; Nathan Smith; Ariadne Rivera-Aguirre; Corey S Davis; David S Fink; Alvaro Castillo-Carniglia; Stephen G Henry; Brandon D L Marshall; Paul Gruenewald; Magdalena Cerdá Journal: Int J Drug Policy Date: 2019-10-15
Authors: Shane R Mueller; Jason M Glanz; Anh P Nguyen; Melanie Stowell; Stephen Koester; Deborah J Rinehart; Ingrid A Binswanger Journal: Int J Drug Policy Date: 2021-01-08
Authors: Julia Dickson-Gomez; Sarah Krechel; Antoinette Spector; Margaret Weeks; Jessica Ohlrich; H Danielle Green Montaque; Jianghong Li Journal: Subst Abuse Treat Prev Policy Date: 2022-07-21